Compare · CLYM vs NVO
CLYM vs NVO
Side-by-side comparison of Climb Bio Inc. (CLYM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLYM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 306.4x CLYM ($727.2M).
- Over the past year, CLYM is up 748.2% and NVO is down 21.8% - CLYM leads by 769.9 points.
- CLYM has been more active in the news (8 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for CLYM).
- Company
- Climb Bio Inc.
- Novo Nordisk A/S
- Price
- $12.68+0.75%
- $50.31-2.25%
- Market cap
- $727.2M
- $222.81B
- 1M return
- +18.28%
- +15.47%
- 1Y return
- +748.16%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 5
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CLYM
- SEC Form SCHEDULE 13G filed by Climb Bio Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Climb Bio Inc.
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Celebi Breanna Maurine
- SEC Form 3 filed by new insider Celebi Breanna Maurine
- SEC Form 8-K filed by Climb Bio Inc.
- President and CEO Brennan Aoife converted options into 68,750 shares and sold $406,979 worth of shares (30,902 units at $13.17) as part of a pre-agreed trading plan, increasing direct ownership by 76% to 87,731 units (SEC Form 4) (withholding tax)
- SEC Form 144 filed by Climb Bio Inc.
- SEC Form 8-K filed by Climb Bio Inc.
- SEC Form 424B5 filed by Climb Bio Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S